All questionsDosing and administration: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer2 questions · 3 sourcesDosingWhat is the KEYTRUDA dose for high-risk early-stage TNBC?“Adult patients with high-risk early-stage TNBC 200 mg every 3 weeks or 400 mg every 6 weeks Administer KEYTRUDA prior to chemotherapy when given on the same day. Neoadjuvant treatment in combination with chemotherapy for 24 weeks (8 doses of 200 mg every 3 weeks or 4 doses of 400 mg every 6 weeks) or until disease progression or unacceptable toxicity, followed by adjuvant treatment with KEYTRUDA as a single agent for up to 27 weeks (9 doses of 200 mg every 3 weeks or 5 doses of 400 mg every 6 weeks) or until disease recurrence or unacceptable toxicity‡” (opens the source at this quote in a new tab)CopyFlag“Patients who experience disease progression or unacceptable toxicity related to KEYTRUDA with neoadjuvant treatment in combination with chemotherapy should not receive adjuvant single agent KEYTRUDA.” (opens the source at this quote in a new tab)CopyFlag“Administer diluted solution via infusion pump intravenously over 30 minutes through an intravenous line containing a sterile, nonpyrogenic, low-protein binding 0.2 to 5 micron in-line or add-on filter.” (opens the source at this quote in a new tab)CopyFlagCan the KEYTRUDA dose be reduced for side effects?“No dose reduction for KEYTRUDA is recommended. In general, withhold KEYTRUDA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue KEYTRUDA for: Life-threatening (Grade 4) immune-mediated adverse reactions. Recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment. An inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids.” (opens the source at this quote in a new tab)CopyFlag